People on the Move
Array BioPharma
Clinical oncologist Victor Sandor has joined Array BioPharma as Chief Medical Officer.
The Colorado-based pharma company develops targeted small-molecule oncology drugs, especially inhibitors. It owns haematology drug filanesib (ARRY-520) for multiple myeloma, and is partnered with AstraZeneca for cancer drug selumetinib, and with Novartis for binimetinib (MEK162).
Sandor will lead activities for binimetinib, an MEK (mitogen-activated protein kinase) inhibitor for ovarian cancer and melanoma currently in Phase III trials. He has previously worked in senior positions at Incyte, Biogen, and AstraZeneca, where he helped bring cancer drugs Jakafi (ruxolitinib), Arimidex (anastrozole) and Faslodex (fulvestrant injection) to market.
(Picture credit: Stephen Depolo/Flickr)
